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Personal data is increasingly collected and used in the context of digital services. 
Consequently, the amount of personal data stored in information systems is increasing 
exponentially. Besides the primary purpose, collected personal data is used for so called 
secondary purposes, such as for monitoring the quality of provided services, in the 
development of new services or products and for scientific research. In general, secondary 
use is permitted under certain conditions by the General Data Protection Regulation (GDPR). 
Additionally, specific legislation addressing secondary use of health data and biobanking has 
been implemented in some countries, including Finland1,2.  
VTT initiated the PreMed project in 2017 with the objective of promoting the development of a 
data-driven precision medicine ecosystem in Finland. In particular, the project aimed at 
collecting different kinds of companies together with the common objective of exploiting the 
opportunities provided by health data resources. The project partners represent different roles 
of the data-driven precision medicine ecosystem as shown in Figure 1. 
In the first phase of the project (May 2017-October 2018) VTT carried out a series of interviews 
for better understanding of the expectations of companies towards exploitation of data and for 
identifying the bottlenecks and challenges faced today. The results of the interviews and the 
analysis of the data-driven precision medicine landscape were compiled into the PreMed 
phase 1 report3. In phases 2 and 3 the main project activity was focused in executing a 
retrospective cohort study on pharmacogenomics (PreMed study). The objective of the study 
was to use data from biobanks and national registries to assess the relevance of using genetic 
data in the context of antithrombotic drug therapy. Besides the scientific objectives, the biobank 
study was expected to provide valuable information and experience on data access processes 
and related bottlenecks. Additionally, the project has developed a system dynamics model for 
simulating alternative precision medicine ecosystem development scenarios. The activities 
related to the planning of the biobank study and development of the simulator were 
documented in the PreMed phase 2 (November 2018 – December 2019) report4.  
This report focuses on the results of the PreMed phase 3 (January  2020 – April 2021). The 
report provides an overview of the activities and achieved results. More detailed information 
can be found in the published articles [1, 2] and conference presentations5. Overall project 
information can be found at the project website6.     
 
1 Biobank Act, https://www.finlex.fi/fi/laki/kaannokset/2012/en20120688.pdf 
2 Act on the secondary use of health and social data, https://stm.fi/en/secondary-use-of-health-and-
social-data 
3 PreMed phase 1 report, https://cris.vtt.fi/en/publications/data-driven-precision-medicine-ecosystem-
stakeholder-needs-and-op 
4 PreMed phase 2 report, https://cris.vtt.fi/en/publications/data-driven-precision-medicine-premed-
phase-2-report 
5 A System Dynamics Model of Data-Driven Precision Medicine Ecosystem   
https://cris.vtt.fi/en/publications/a-system-dynamics-model-of-data-driven-precision-medicine-ecosyst 









Figure 1. Data-driven precision medicine ecosystem showing roles of PreMed partners.  
 
 





2. Overview of project activities 
Activities carried out during phase 3 of the project are shown in Figure 2. The ecosystem model 
was further developed during the first half of year 2020 after which the model and simulation 
results were reported in a conference presentation in July. Most of the phase 3  effort was 
invested in carrying out the biobank study. The data collection was completed in May followed 
by the data analysis and reporting phases. Three project workshops were organized during 
phase 3. The project activities and obtained results are described in more detail in the following 
sections.   
   
  
Figure 2. PreMed project activities during phase 3. 
3. Biobank study organisation 
An important objective of the project was to collect experiences of the process of applying data 
permits and integrating the data from heterogeneous sources for analysis. The experiences 
are reported in [2]. The data sources for the study were Auria Biobank, Helsinki Biobank, 
Finnish Institute of Health and Welfare (THL), THL Biobank, Finnish Prescription Register 
(Kela) and Finnish Hospital districts and municipalities.  
The data collection process and timeline are depicted in Figures 3 and 4. VTT first submitted 
the application for ethical review and then data permit applications to the biobanks, THL and 
Kela. After the applications were accepted biobanks started data integration. Each biobank 
formed a subcohort by linking their genome and patient record data with THL and Kela register 
data as well as with laboratory data from hospital districts and municipalities. The subcohorts 
were delivered to VTT in pseudonymized form (without personal identifiers).  VTT integrated 
the full cohort by combining the subcohorts. 
The study showed that a large cohort of patient data can be formed by integrating various data 
resources. Co-operation with all partners was smooth. However, as this was one of the first 
projects where data resources across several biobanks were combined, the practices for co-
operation were not fully established and needed to be defined during the project. The data 
quality was observed to be good in general [2]. The medication data extracted from hospital 
data lakes was incomplete (as informed beforehand by the biobanks), but still useful in 
complementing drug dispensation data of Kela. The full data collection process took 16 months 
(from January 2019 to May 2020) and required an effort of approximately 5 months from VTT 
researchers.  The data costs, including applications and data extraction of biobank and 
national register data, were approximately 80 000 €. The long and laborious data collection 
phase is clearly a challenge for both industrial and academic use of data. Especially, it was 
affected by the congested data permit service of THL register authority. The data collection 
could not be fully proceeded before all data permits were granted. This caused idle periods of 
several months. Improvement will hopefully be achieved via the centralized “one stop shop” 
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services of Findata, which were not yet available for the PreMed project. The process related 
to using biobank resources linked with register data will be regulated by the new biobank law 
currently in preparation1.  
 
    














Figure 4. Data collection timeline.  
 
4. Data analysis 
In the framework of the PreMed project the following drugs were investigated:  
 
• warfarin 
• direct oral anticoagulants, DOACs (dabigatran, rivaroxaban, apixaban) 
• ticagrelor  
 
The data analysis was mostly focused in investigating associations between single nucleotide 
variants (SNV’s) and clinical outcomes. Candidate variants to be investigated for each drug 
were based on earlier studies as defined in the study protocol1.  We also compared the 
healthcare costs of different genotype groups in warfarin users to assess possible cost savings 
achievable by genotype-guided drug therapy.  
 
Overview of the results is presented in the following subsections. Results on warfarin and 
DOAC pharmacogenetics have been reported in [1] and [3]. Articles on ticagrelor 
pharmacogenetics and on the impact of pharmacogenetics on warfarin therapy costs are being 
written.  
 
Additionally, investigation of clopidogrel pharmacogenetics is ongoing as a separate research 
activity at VTT as enabled by the granted data permits.    
4.1 Methods  
Investigation of associations between genetic variants and clinical outcomes was based on 
comparing the incidence of outcome events between patients with different genotypes. Cox 
proportional hazards model was used in these comparisons and for adjusting of confounders.  
 








In the case of warfarin, also parameters derived from international normalized ratio (INR) 
measurements were used as outcome indicators.   
We compared normal responders to the group of sensitive or highly sensitive responders [4] 
to warfarin. This approach enables the combined effect of the most important variants of the 
CYP2C9 and VKORC1 to be analysed. In the case of DOACs we studied the genetic 
associations using both genotype and haplotype based groups. The haplotypes were 
estimated from the genotype data by using the PHASE (v2.1.1) software package [5]. 
For the investigation of the impact of pharmacogenetics on warfarin therapy we analysed 
separately healthcare visit costs, medication costs and laboratory costs. Healthcare visit costs 
were further divided according to the reason for the visit (bleeding or thromboembolic event) 
and the type of the visit (outpatient visit or hospital stay). The medication costs were calculated 
based on purchased amount and the drug price. Laboratory costs were calculated from the 
number of laboratory tests and the nominal price of one laboratory test [6]. The costs of 
encounters were based on the nominal prices of outpatient visits and hospital days defined 
separately for primary and secondary care [7].       
4.2 Warfarin 
Warfarin is still currently the most used anticoagulant in Finland with 110 072 users in 20191. 
The pharmacogenetics of warfarin has been extensively studied before [8], but not in the 
Finnish population.  
 
PreMed study cohort included 2508 warfarin users [1]. The results show that the sensitive or 
highly sensitive patients group had more INR measurements above the normal therapy window 
(INR=2-3) and that normal responders had more INR measurements below the normal therapy 
window. This difference, however, did not translate into clinical outcomes as expected: there 
was no statistically significant difference in the bleeding events between the groups. Instead, 
thromboembolic events were more common in the sensitive or highly sensitive group. This is 
expected to be a consequence of the fact that INR test results are used in defining the required 
dose and, therefore, high INR values lead to lowering the dose. This may have led to too small 
doses or even pauses in the warfarin treatment, and consequently, increased the risk of 
thromboembolic events.  The detailed results have been published in [1].  
 
4.3 Direct oral anticoagulants 
Direct oral anticoagulants are new anticoagulation drugs rapidly becoming more popular due 
to their favourable pharmacodynamic and pharmacokinetic properties and since they do not 
normally require continuous therapeutic monitoring. In 2019 there were 19981 dabigatran 
users, 57619 rivaroxaban users, 62858 apixaban users and 6949 edoxaban users in Finland. 
Pharmacogenetics of DOACs have been investigated by earlier studies, but only in a few cases 
associations between genetic variants and clinical outcomes have been found [9]. Most of the 
earlier studies have investigated the pharmacokinetics of DOACs but not the related clinical 
outcomes. The PreMed study is to our knowledge the first register-based real world data study 
addressing the association between genetic variants and clinical outcomes in DOAC users.  
 
The PreMed study cohort included 340 dabigatran users, 999 rivaroxaban users and 467 
apixaban users. Edoxaban users were not included in the analysis as data for only 25 patients 
was available.   
 
 









As laboratory measurements are not systematically taken to guide DOAC therapy, it was not 
possible to use parameters derived from laboratory measurements as outcome indicators. 
Therefore, only bleeding and thromboembolic events were used as outcome indicators. We 
found two of the investigated SNV’s of the ABCB1 gene to be associated with thromboembolic 
events in rivaroxaban users and corresponding results were seen also in the haplotype-based 
analysis. We also found one of the investigated ABCB1 SNV’s to be associated with bleeding 
events in apixaban users. The detailed results will be reported in an article submitted for 
publication [3]. 
 
4.4 Ticagrelor  
Ticagrelor is the first of new class antiplatelet agents with 8423 users in Finland in 20191. 
Characteristics of ticagrelor overcome some of the limitations of dual antiplatelet therapy with 
aspirin and clopidogrel: ticagrelor is rapidly absorbed, it does not require metabolic activation 
to an active form, it binds rapidly and reversibly to the P2Y12 receptor, its pharmacokinetic 
profile is not significantly affected by age, gender or administration with food, and its 
pharmacodynamic characteristics are not affected by CYP2C19 and ABCB1 SNVs [10].   
This study investigated if CYP3A5*3, CYP3A4*22 and CYP4F2 variants were associated with 
incidence of bleeding in ticagrelor-treated patients in the PreMed cohort (n=368). We found 
that carriers of CYP3A4*22 had increased risk of bleeding compared to CYP3A4*22 non-
carriers. No associations were found between bleeding incidence and CYP3A5*3 or CYP4F2 
carrier status. Studies with larger populations are needed to confirm this finding. The detailed 
results will be reported in an article currently being prepared. 
4.5 Comparison of warfarin therapy costs between genotypes  
We compared costs accrued during the warfarin exposure period between normal and 
sensitive or highly sensitive patients. The comparison was based on the same set of 2508 
patients that was analysed for associations between genotypes and outcome events [1].  
 
According to the results, the medication costs were lower for the group of sensitive and highly 
sensitive responders due to the fact that their daily warfarin dose was smaller in average.  
Laboratory costs and costs of healthcare visits related to bleeding events were higher for the 
sensitive and highly sensitive responders although statistical significance was not achieved. 
However, the difference between the groups in costs of visits related to bleeding events was 
close to statistical significance (p=0.064). This finding is in line with the expected elevated risk 
of over-anticoagulation in sensitive and highly sensitive patients. However, the finding 
contradicts our earlier analysis where we could not see a significant association between the 
genotype and bleeding events [1]. The reason seems to be that sensitive or highly sensitive 
responders have more severe or frequent bleeding episodes requiring more outpatient and 
hospital visits, while there is no difference in the number of patients experiencing bleeding 
















4.6 Usage of pharmacogenetic tests 
Pharmacogenetic tests are commercially available and physicians may order them in the 
context of prescribing drugs with known pharmacogenetic properties1 [11]. Warfarin is one of 
the drugs for which such test is available. Based on the laboratory data we found that the 
pharmacogenetic test (code: B -Farma-D or B -Varfa-D) had been taken only for 7 individuals 
(0.28%) in the group of 2508 patients.      
5. Ecosystem simulation  
The data-driven precision medicine ecosystem is expected to lead to remarkable economic 
benefits through new products and business opportunities. However, considerable public 
investments are needed to establish the required infrastructure (data/samples, biobank 
processes), to accelerate the R&D of ecosystem companies and to support related academic 
research. For decision-makers an important question is how to support the data-driven 
precision medicine ecosystem growth to achieve maximum benefit for the society. The PreMed 
project has developed a system dynamics model for simulation of alternative development 
paths of the ecosystem.  Figure 5 shows the high-level ecosystem diagram indicating 
alternative targets for public investments. The primary outcome measure is the volume of 
research projects making use of data obtained from biobanks and national registers.  The 
simulator was implemented using the Vensim simulation software2 
 
Figure 5. High-level ecosystem model showing main stakeholder groups and dependences 
affecting the exploitation of health data.  
 
1 Abomics, https://www.abomics.fi/en/ 
 
2 Vensim simulation software, https://vensim.com/vensim-software/ 
 
 





An example of simulation results is presented in Figure 6. The volume of research projects 
based on health data resources initiated by pharmaceutical industry in Finland is shown as a 
function of time. The volume of data-driven research depends on the allocation of resources 
for R&D by the industry and on the pharma companies’ preferences in focusing the resources 
to RWD (real world data) or other data-driven projects. This choice is assumed to be affected 
by the availability of health data (including genomic data) and the quality of the related 
processes (e.g. delivery times and needed resources for data permit applications). In the 
simulation model the quality of the data access processes is linked with public investments in 
the centralized services (Findata) and biobanking.     
In the base scenario of Figure 6 the public investments starting 1.1. 2020 are 5 M€ per year 
for three years for genotyping and 3 M€ per year for five years for Findata services. In the 
increased public investment scenario the yearly investments for Findata are 6 M€ and  the 
investments continue longer: ten years for genotyping and six years for Findata. In the 
increased public and private investment scenario additionally the yearly growth of the R&D 
investments of pharmaceutical industry are increased from the base value of 3% to 5%. 
Realized yearly investments of the pharmaceutical industry in research and in register-based 
research are shown for reference. Description of the simulator and more simulation results of 
various scenarios have been reported in the conference presentation materials available at the 
project web site [12].  
 
Figure 6. Example of ecosystem simulation results. Volume of Finnish pharmaceutical 
industry projects exploiting data resources (“data project volume”) in three simulation cases. 
Realized investments of pharmaceutical industry in research and in register-based research 



















Data project volume / simulation case: base scenario
Data project volume / simulation case: increased public investment
Data project volume / simulation case: increased public and private investment
Research investments (realized)
Register-based research investments  (realized)
 
 




6. Discussion and conclusions 
We have reported results achieved in phase 3 of the PreMed project. The overall objective of 
the project was to promote the development of the data-driven precision medicine ecosystem 
in Finland. Under this overall objective, a biobank study with specific needs for data integration 
from several sources was carried out. Besides the scientific goals, the objective of the biobank 
study was to collect practical information of the data exploitation processes including related 
bottlenecks in order to pave the way for data-driven healthcare.  
The biobank study demonstrated the capability of the Finnish biobanks together with national 
register controllers to provide data resources for research purposes. Such projects integrating 
data from several data sources are not trivial and could not be executed in all countries. Along 
the way, several challenges were faced as reported. Most importantly, the process of data 
permit application and data integration was laborious and long, taking 16 months altogether. 
The PreMed data collection was carried out before Findata services were available. Thus, our 
experiences and observations provide a bench-marking reference for the Findata services 
being developed. We have communicated the faced challenges to Findata in order to support 
the development of new centralized services.  
The obtained data sets were in general of high quality and provided a good basis for the data 
analysis to be carried out in the study. Thanks to the on-going FinnGen project1 and past 
research projects of THL, genotype data is largely available in biobanks for research. By linking 
genotype data with patient record and laboratory data we were able to observe the 
associations between genetic variants and health outcomes.  
The Finnish infrastructure for secondary use of data and biobanking is well-established and 
serves as a model for other countries, where such infrastructure is still developing. However, 
more effort and resources are needed to fully exploit the health data resources in Finland. The 
current processes and practices do not sufficiently support the execution of projects where 
data needs to be combined from several sources. The Government’s bill for a new biobank 
act2 defines Findata to be the permit authority also for biobank materials and data. However, 
the proposed legislation has been largely criticized and, therefore, the content of the law may 
still be considerably modified. Especially, the academic research community sees challenges 
in the legislation on secondary use of data. The worries are related especially to increasing 
costs, sufficiency of Findata’s resources and to the limitations (e.g. concerning available 
computing power) caused by the secure processing environments3.   
There is a need for public-private co-operation in developing an efficient infrastructure for 
health and social data exploitation. The PreMed project developed a system dynamics model, 
which can be used for simulation of the evolution of the data-driven ecosystem. The simulator 
enables different public investment scenarios to be investigated e.g. by comparing their effects 
on the volume of data-driven projects initiated by the pharmaceutical industry. The input 
parameters of the model include available statistical data such as the pharmaceutical R&D and 
real world data project investments as well as the amount of biobank consents.  
The simulation model involves several unknown factors. For example, we do not know the 
effect of data availability on the R&D project initiation and such parameters needed to be 
estimated. Even with limited input data, we expect that the model is useful in comparison of 
different alternative development paths. As more information on the data exploitation 
processes accumulate the model parameters can be defined more realistically. The model was 
 
1 FinnGen project, https://www.finngen.fi/en 
2 https://stm.fi/hanke?tunnus=STM110:00/2015 
3 Toisiolain vaikutukset tutkimukseen ja data-analytiikan sovelluksiin: Hyteairon analytiikkatyöryhmän 









constructed from the perspective of pharmaceutical industry, but could be extended to other 
sectors in further development.  
The objective of the biobank study carried out in the project was to investigate the 
pharmacogenomics of antithrombotic drugs. In the framework of the PreMed project we were 
able to complete the analyses on 4 anticoagulants (warfarin dabigatran, rivaroxaban, 
apixaban) and one antiplatelet (ticagrelor). The results on warfarin pharmacogenetics have 
already been published while another article on dabigatran, rivaroxaban and apixaban has 
been submitted for publication. Article on Ticagrelor pharmacogenetics and costs aspects of 
warfarin pharmacogenetics are being written. The analysis on other drugs – especially 
clopidogrel - is being continued in the framework of VTT’s internal research activity.  The 
results obtained so far indicate associations between genotypes and clinical outcomes in 
warfarin, rivaroxaban, apixaban and ticagrelor users. The results increase our understanding 
of the impact of genetics on the effects of these drugs and may aid in identifying individuals 
with suboptimal response to the drug therapy. Further research is warranted on the clinical 
impact and cost-effects of pharmacogenetic variability in the drug response. 
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